Skip to main content

Janku Filip's Form 4 filing

Monte Rosa Therapeutics, Inc. (GLUE) · filed Jul 1, 2026

Accession no.
0001193125-26-292767
Filed
Jul 1, 2026, 4:57 PM ET
Trade date
Jun 30, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $132.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Janku FilipCIK 0001862930Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 30, 2026Common StockMOption exerciseAcquired+5,407$13.41+$72,507.8766,019Direct
Jun 30, 2026Common StockSSaleDisposed−5,407$24.50−$132,471.560,612Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 30, 2026Common StockMOption exerciseDisposed−5,407$0.00$081,093Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)